jRCT2080222723已完成2 期
Phase IIa Study of F-1311 in Patients with Prostate Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, Open-label
- 主要目的
- Diagnostic Purpose
入排标准
- 年龄范围
- 20age old over 至 No limit（—）
- 性别
- Male
入选标准
- •Biopsy confirmed presence of adenocarcinoma of the prostate gland.
- •Gleason score >= 7
- •PSA > 20 ng/mL
排除标准
- •Subjects have received or have been receiving treatment or medication for prostate cancer.
- •Subjects have severe hepatic or renal dysfunction.
结局指标
主要结局
-
efficacy Ability of F-1311 to accumulate in prostate cancer
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Phase IIa Study of F-1311 in Patients with Prostate CancerProstate cancerJPRN-jRCT2080222723PDRadiopharma Inc.15
已完成
2 期
Phase IIb Study of F-1311 in Patients with Prostate CancerProstate CancerJPRN-jRCT2080223135PDRadiopharma Inc.56
已完成
2 期
Phase IIb Study of F-1311 in Patients with Prostate CancerProstate CancerjRCT2080223135PDRadiopharma Inc.56
进行中（未招募）
不适用
A Clinical Phase II Study in Patients with Prostate Cancer and Bone Metastases with KML001 (KOMINOX®) - KML001 in patients with prostate cancer and bone metastasesProstate Cancer MetastaticMedDRA version: 8.1Level: LLTClassification code 10036909Term: Prostate cancer metastaticEUCTR2006-005607-33-DEKOMINOX USA, Inc.
进行中（未招募）
1 期
A Phase 1/2, Open-Label Study in Men with Prostate Cancer to Assess the Safety, Pharmacokinetics, and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1 Month Depot, Including a Randomized Portion With a Group Administered LeuproreliMedDRA version: 12.1Level: LLTClassification code 10007113Term: Cancer of prostateProstate cancerEUCTR2009-017668-18-FRMillennium Pharmaceuticals, Inc.